Dry Eye Disease (DED) is a multifactorial pathology characterized by inflammation of the lacrimal functional unit that develops in ocular surface pathology, severely affecting patients quality of life. The core of the treatment relies at present in antinflammatory topical therapies, which are still scarce. The investigators hypothesize that osteopathy-based techniques may help these patients by influencing the central involvement regarding parasympathetic innervation of tear and saliva-secreting glands. The aim of this osteopathic treatment protocol is to release the involved structures in the tear-secreting system innervation, such as the sphenopalatine ganglion. In addition, this ganglion innervates the minor salivary glands, therefore it is intended to help patients suffering from xerostomia. The hypothesis then is that a systemic protocol treatment can help balance both parts of the vegetative nervous system (sympathetic and parasympathetic) with the objective of increasing the secretion of tear and saliva in patients with ocular and oral dryness (DED and xerostomia, respectively), thus improving their clinical situation. This osteopathic protocol does not have the potential to cause adverse effects. The main objective is to analyze the efficacy of this protocol application in terms of improving symptoms and signs of ocular and oral dryness, tear film quality and inflammation molecule levels in tears and saliva.
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Ocular Surface Disease Index (OSDI)
Timeframe: 6 Weeks
Ocular Surface Disease Index (OSDI)
Timeframe: 18 Weeks
Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)
Timeframe: 6 Weeks
Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)
Timeframe: 18 Weeks
Visual analogue Scale (VAS)
Timeframe: 6 Weeks
Visual analogue Scale (VAS)
Timeframe: 18 Weeks
Change in Dry Eye Symptoms Questionnaire (CDES-Q)
Timeframe: 6 Weeks
Change in Dry Eye Symptoms Questionnaire (CDES-Q)
Timeframe: 18 Weeks
Statistically significant amelioration in oral symptoms
Timeframe: 6 Weeks
Statistically significant amelioration in oral symptoms
Timeframe: 18 Weeks
Statistically significant improvement in tear secretion
Timeframe: 6 Weeks
Statistically significant improvement in tear secretion
Timeframe: 18 Weeks
Statistically significant improvement in salivary discharge
Timeframe: 6 Weeks
Statistically significant improvement in salivary discharge
Timeframe: 18 Weeks